These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 15126650)

  • 1. Improving phosphate-binder therapy as a way forward.
    Hutchison AJ
    Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i19-24. PubMed ID: 15126650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients.
    Albaaj F; Hutchison AJ
    Int J Clin Pract; 2005 Sep; 59(9):1091-6. PubMed ID: 16115187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphate binder usage in kidney failure patients.
    Bleyer AJ
    Expert Opin Pharmacother; 2003 Jun; 4(6):941-7. PubMed ID: 12783590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients.
    Albaaj F; Hutchison AJ
    Expert Opin Pharmacother; 2005 Feb; 6(2):319-28. PubMed ID: 15757427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of new phosphate binders for chronic renal failure.
    Loghman-Adham M
    Drug Saf; 2003; 26(15):1093-115. PubMed ID: 14640773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients.
    Almirall J; Lopez T; Vallve M; Ruiz A; Llibre J; Betriu A
    Nephron Clin Pract; 2004; 97(1):c17-22. PubMed ID: 15153763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperphosphataemia in renal failure: causes, consequences and current management.
    Albaaj F; Hutchison A
    Drugs; 2003; 63(6):577-96. PubMed ID: 12656655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic potential of novel phosphate binders.
    Querfeld U
    Pediatr Nephrol; 2005 Mar; 20(3):389-92. PubMed ID: 15650884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving outcomes in hyperphosphataemia.
    De Broe ME; D'Haese PC;
    Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i14-8. PubMed ID: 15126649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lanthanum: new drug. Hyperphosphataemia in dialysis patients: more potential problems than benefits.
    Prescrire Int; 2007 Apr; 16(88):47-50. PubMed ID: 17458039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lanthanum carbonate.
    Freemont AJ
    Drugs Today (Barc); 2006 Dec; 42(12):759-70. PubMed ID: 17285149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
    Sprague SM
    Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lanthanum carbonate as a first-line phosphate binder: the "cons".
    Drüeke TB
    Semin Dial; 2007; 20(4):329-32. PubMed ID: 17635823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperphosphataemia and treatment with sevelamer in haemodialysis patients.
    Cizman B
    Nephrol Dial Transplant; 2003 Jul; 18 Suppl 5():v47-9. PubMed ID: 12817070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lanthanum carbonate: a new phosphate binder.
    Behets GJ; Verberckmoes SC; D'Haese PC; De Broe ME
    Curr Opin Nephrol Hypertens; 2004 Jul; 13(4):403-9. PubMed ID: 15199290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis.
    Huybrechts KF; Caro JJ; Wilson DA; O'Brien JA
    Value Health; 2005; 8(5):549-61. PubMed ID: 16176493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sevelamer.
    Henderson J; Altmann P
    Nephron Clin Pract; 2003; 94(3):c53-8. PubMed ID: 12902631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term comparison of a calcium-free phosphate binder and calcium carbonate--phosphorus metabolism and cardiovascular calcification.
    Braun J; Asmus HG; Holzer H; Brunkhorst R; Krause R; Schulz W; Neumayer HH; Raggi P; Bommer J
    Clin Nephrol; 2004 Aug; 62(2):104-15. PubMed ID: 15356967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.
    Chudek J; Piecha G; Kokot F; Wiecek A
    J Nephrol; 2003; 16(5):710-5. PubMed ID: 14733418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia.
    Pai AB; Smeeding JE; Brook RA
    Curr Med Res Opin; 2004 Jul; 20(7):991-9. PubMed ID: 15265243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.